STELLA PHARMA CORPORATION [4888.T]
TOKYO, May 20 (Pulse News Wire) – Stella Pharma Corporation (4888.T) has decided to propose several board member appointments and reappointments at its upcoming 19th Ordinary General Meeting of Shareholders scheduled for June 24, 2026. The final decisions on roles and responsibilities will be made during the subsequent board meeting on the same day.
Key appointees include: - Uehara Koki, currently serving as President and CEO, who will continue in his role. - Yabu Kazumitsu, currently overseeing sales operations, will retain his position. - Hayashi Tomimitsu, currently leading the Pharmaceutical Affairs Department and Clinical Development Department, will remain in his post. - Kitoh Takahiro, currently heading Corporate Planning, will stay in his existing capacity. Additionally, the company plans to retire Director Masaya Onishi, who serves as an external director and audit committee member, effective upon the conclusion of the shareholders' meeting.
Newly appointed candidates for the audit committee positions include: - Tsujii Kohei, currently serving as an external director and audit committee member, will be reappointed. - Fukuchi Yoshiyuki, also an external director and audit committee member, will be reappointed. - Machida Misa, newly nominated, will take up the role of external director and audit committee member. since January 2025. The company also intends to reappoint Takei Yukio as a supplementary audit committee member.
🟡 Confidence: Standard AI-translated content.